Niki BioSolutions, Inc. appointed Ian Huen as CEO and Alidad Mireskandari as COO following a previously announced merger transaction. Mr. Huen’s appointment letter, effective August 1, 2026, provides a monthly base salary of HKD 210,000 (approximately USD 26,800) and discretionary bonuses. Mr. Mireskandari’s employment agreement grants an annual base salary of $320,000, with performance bonuses up to 50% of base salary, 20,000 restricted stock units vesting at merger closing, and options for 800,000 shares. The company operates in the biotechnology sector.

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) consummated its merger with DiamiR Biosciences Corp. on July 20, 2026, following a domestication to Delaware and a name change. Concurrently, the company effected a one-for-10 reverse stock split effective July 20, 2026. The filing furnishes unaudited interim consolidated financial statements for the six months ended June 30, 2026, reporting a net loss of $1,307,300 and cash on hand of $1,834,171. Management has identified substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows. The biopharmaceutical company researches and develops life science and therapeutic products.

Niki BioSolutions, Inc. regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. The company received a deficiency letter on March 5, 2026, after its stock closed below $1.00 for 30 consecutive business days. On August 4, 2026, Nasdaq confirmed that the closing bid price remained at or above $1.00 for ten consecutive business days from July 21 to August 3, 2026, resolving the compliance matter. Niki BioSolutions operates in the biotechnology industry, focusing on drug discovery and development.